Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymosin alpha 1 plus standard chemotherapy in metastatic EGFR wild-type NSCLC
2015-005605-36Phase 2Terminated
- Sponsor
- SciClone Pharmaceuticals (Holdings) Limited
- Start
- Jan 2019
- Modality
- Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of thymosin alpha 1 in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by SciClone Pharmaceuticals (Holdings) Limited. Primary endpoint: Progression-free survival (PFS). Started Jan 2019; status: terminated.
02
Drugs
thymosin alpha 1
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2015-005605-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005605-36.